keyword
MENU ▼
Read by QxMD icon Read
search

"febrile neutropenia"

keyword
https://www.readbyqxmd.com/read/29149345/predictive-indicators-to-identify-high-risk-paediatric-febrile-neutropenia-in-paediatric-oncology-patients-in-a-middle-income-country
#1
Lindy-Lee Green, Pierre Goussard, Anel van Zyl, Martin Kidd, Mariana Kruger
Purpose: To validate a clinical risk prediction score (Ammann score) to predict adverse events (AEs) in paediatric febrile neutropenia (FN). Patients and methods: Patients <16 years of age were enrolled. A risk prediction score (based on haemoglobin ≥ 9 g/dl, white cell count (WCC) < 0.3 G/l, platelet count <50 G/l and chemotherapy more intensive than acute lymphoblastic leukaemia maintenance therapy) was calculated and AEs were documented. Results: In total, 100 FN episodes occurred in 52 patients, male:female ratio was 1...
November 15, 2017: Journal of Tropical Pediatrics
https://www.readbyqxmd.com/read/29148638/factors-associated-with-treatment-outcome-of-pediatric-cancerpatients-admitted-with-febrile-neutropenia-in-tikuranbessa-specialized-teaching-hospital-addis-ababa-ethiopia
#2
Selamawit Assefa, Tinsae Alemayehu, Workeabeba Abebe
Background: Cancer treatment is associated with variable degrees of myelosupression. Infection is often a life-threatening complication of chemotherapy-induced neutropenia, and it is also considered an oncologic emergency. Febrile neutropenia is a common, costly and potentially fatal complication in oncology. Objective: To assess factors affecting treatment outcome of cancer patients with chemotherapy induced febrile neutropenia. Method: We conducted a review of records of pediatric patients hospitalized and treated for chemotherapy-induced febrile neutropenia from January 1, 2013 to December 31, 2013 and met the selection criteria...
January 2017: Ethiopian Medical Journal
https://www.readbyqxmd.com/read/29147869/hematological-adverse-effects-in-breast-cancer-patients-treated-with-cyclin-dependent-kinase-4-and-6-inhibitors-a-systematic-review-and-meta-analysis
#3
REVIEW
Loay Kassem, Kyrillus S Shohdy, Shaimaa Lasheen, Omar Abdel-Rahman, Thomas Bachelot
BACKGROUND: The introduction of specific cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors significantly improved progression-free survival in hormone receptor-positive metastatic breast cancer. CDK 4/6 inhibitors induce cell cycle arrest via liberating the tumor suppressor retinoblastoma protein from CDK4/6 inhibitory effect. Preliminary studies suggested an increase in the hematological toxicities which might affect the quality of life in such palliative setting. METHODS: We searched PubMed, ASCO, ESMO and San Antonio meeting databases for randomized phase II/III trials in metastatic breast cancer receiving CDK4/6 inhibitors with safety data provided on the incidence of hematological adverse effects...
November 16, 2017: Breast Cancer: the Journal of the Japanese Breast Cancer Society
https://www.readbyqxmd.com/read/29139135/phase-1-study-of-quizartinib-in-combination-with-induction-and-consolidation-chemotherapy-in-patients-with-newly-diagnosed-acute-myeloid-leukemia
#4
Jessica K Altman, James M Foran, Keith W Pratz, Denise Trone, Jorge E Cortes, Martin S Tallman
Novel therapies have potential to improve outcomes in patients with acute myeloid leukemia (AML) harboring FLT3-ITD mutations that have high risk of relapse and poor survival following standard of care (SOC) cytarabine/anthracycline-based induction/consolidation chemotherapy. Quizartinib is a selective and highly potent FLT3 inhibitor that has shown strong single-agent activity in relapsed or refractory (R/R) AML. This phase 1, open-label, sequential group dose-escalation trial (NCT 01390337) is the first evaluating safety and tolerability of quizartinib in combination with SOC chemotherapy in newly diagnosed AML (ndAML)...
November 15, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/29136201/safety-and-tolerability-of-selumetinib-as-a-monotherapy-or-in-combination-with-docetaxel-as-second-line-therapy-in-japanese-patients-with-advanced-solid-malignancies-or-non-small-cell-lung-cancer
#5
Takashi Seto, Fumihiko Hirai, Hideo Saka, Yoshihito Kogure, Kiyotaka Yoh, Seiji Niho, Kenjiro Fukase, Hitoshi Shimada, Michitaka Sasai, Koichi Fukino
Objective: This Phase I study (NCT01605916) investigated the safety, tolerability and pharmacokinetic profile of selumetinib plus docetaxel as second-line therapy in Japanese patients with locally advanced or metastatic non-small cell lung cancer (NSCLC), or selumetinib monotherapy in Japanese patients with advanced solid malignancies. Methods: All enrolled patients received single-dose selumetinib 25, 50 or 75 mg, followed by a 3-day washout. Combination therapy cohorts then started a 21-day cycle of docetaxel 60 mg/m2 plus selumetinib 25 or 75 mg twice-daily (BID) on Day 1...
November 10, 2017: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29124328/efficacy-of-combination-chemotherapy-using-irinotecan-and-nedaplatin-for-patients-with-recurrent-and-refractory-endometrial-carcinomas-preliminary-analysis-and-literature-review
#6
Morikazu Miyamoto, Masashi Takano, Mika Kuwahara, Hiroaki Soyama, Kento Kato, Hiroko Matuura, Takahiro Sakamoto, Kazuki Takasaki, Tadashi Aoyama, Tomoyuki Yoshikawa, Kenichi Furuya
PURPOSE: We aimed to retrospectively evaluate the efficacy and toxicity of an irinotecan hydrochloride (CPT) and nedaplatin (N) combination therapy for recurrent and refractory endometrial carcinoma, administered based on UGT1A1 genotype. METHODS: Between 2009 and 2017, 21 patients who received CPT-N therapy for recurrent endometrial carcinoma as second- or third-line chemotherapy at our hospital were identified. The CPT-N regimen included 40-70 mg/m(2) of CPT-11 on days 1, 8, and 15, and 50 mg/m(2) of nedaplatin on day 1, q4 weeks...
November 9, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/29115709/safety-of-discharge-for-children-with-cancer-and-febrile-neutropenia-off-antibiotics-using-absolute-neutrophil-count-threshold-values-as-a-surrogate-marker-for-adequate-bone-marrow-recovery
#7
Matthew E Campbell, Debra L Friedman, Daniel E Dulek, Zhiguo Zhao, Yi Huang, Adam J Esbenshade
BACKGROUND: Febrile neutropenia (F&N) is common among pediatric oncology patients. However, there is a lack of clarity regarding parameters whereby such patients have demonstrated adequate bone marrow recovery for hospital discharge and empiric antibiotic discontinuation. PROCEDURE: A retrospective review was performed for 350 episodes of F&N occurring at a single institution between 2007 and 2012 in pediatric oncology patients who were afebrile for 24 hr and had no bacterial source identified...
November 8, 2017: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/29108384/efficacy-safety-and-proper-dose-analysis-of-pegylated-granulocyte-colony-stimulating-factor-as-support-for-dose-dense-adjuvant-chemotherapy-in-node-positive-chinese-breast-cancer-patients
#8
Fan Zhang, RuiXia LingHu, XingYang Zhan, Ruisheng Li, Fan Feng, Xudong Gao, Lei Zhao, Junlan Yang
For high-risk breast cancer patients with positive axillary lymph nodes, dose-dense every-two-week epirubicin/cyclophosphamide-paclitaxel (ddEC-P) regimen is the optimal postoperative adjuvant therapy. However, this regimen is limited by the grade 3/4 neutropenia and febrile neutropenia (FN). There is an urgent need to explore the efficacy, safety and proper dosage of PEGylated granulocyte colony-stimulating factor (PEG-G-CSF) as support for ddEC-P in Chinese breast cancer patients with positive axillary lymph nodes...
October 3, 2017: Oncotarget
https://www.readbyqxmd.com/read/29108332/whether-low-dose-metronomic-oral-cyclophosphamide-improves-the-response-to-docetaxel-in-first-line-treatment-of-non-triple-negative-metastatic-breast-cancer
#9
Jian Zhang, Leiping Wang, Zhonghua Wang, Biyun Wang, Jun Cao, Fangfang Lv, Sheng Zhang, Zhimin Shao, Xichun Hu
Oral metronomic chemotherapy may target tumor cells indirectly via antiangiogenic activity, restoration of anticancer immune response, or induction of tumor dormancy. We initiated the single-center, randomized, open-label, phase II study to determine whether the addition of metronomic cyclophosphamide to docetaxel (T) (w/o trastuzumab) improves overall response rate (ORR) as first-line treatment among patients with non-triple-negative metastatic breast cancer (MBC). Eligible patients with previously untreated non-triple-negative MBC were randomly assigned (1:1) to receive 3-weekly cycles of Metro-TC (T 75mg/m(2), d1 plus oral cyclophosphamide 50 mg daily) or T alone...
October 3, 2017: Oncotarget
https://www.readbyqxmd.com/read/29102858/weekly-cabazitaxel-plus-prednisone-is-effective-and-less-toxic-for-unfit-metastatic-castration-resistant-prostate-cancer-phase-ii-spanish-oncology-genitourinary-group-sogug-trial
#10
Miguel Ángel Climent, Begoña Pérez-Valderrama, Begoña Mellado, Eva María Fernández Parra, Ovidio Fernández Calvo, María Ochoa de Olza, Laura Muinelo Romay, Urbano Anido, Montserrat Domenech, Susana Hernando Polo, José Ángel Arranz Arija, Cristina Caballero, María José Juan Fita, Daniel Castellano
AIM: Cabazitaxel (CBZ), a novel tubulin-binding taxane, improves overall survival in metastatic castration-resistant prostate cancer (mCRPC) that progresses during or after docetaxel treatment. We have designed a phase II study to evaluate the efficacy and safety of CBZ as a weekly schedule for 'unfit' mCRPC patients after docetaxel failure. METHODS: In this single arm phase II study. CBZ was weekly administered in 1-hour infusion on days 1, 8, 15 and 22, every 5 weeks at 10 mg/m(2) to eligible 'unfit' patients; oral prednisone (5 mg) was administered twice a day...
November 2, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/29101518/phase1-study-of-cisplatin-plus-pemetrexed-with-erlotinib-and-bevacizumab-for-chemotherapy-na%C3%A3-ve-advanced-non-squamous-non-small-cell-lung-cancer-with-egfr-mutations
#11
Motohiro Tamiya, Akihiro Tamiya, Takayuki Shiroyama, Sawa Takeoka, Yujiro Naito, Naoki Omachi, Yohei Kimura, Naoko Morishita, Hidekazu Suzuki, Norio Okamoto, Kyoichi Okishio, Tomoya Kawaguchi, Shinji Atagi, Tomonori Hirashima
Background Cisplatin and pemetrexed are very effective against advanced non-squamous non-small cell lung cancer (NSCLC) without EGFR mutations. Erlotinib plus bevacizumab are highly effective against advanced NSCLCs with activating EGFR mutations. We performed this phase I 'Quartet Trial' to determine the safety and efficacy of all 4 agents as a first-line treatment for non-squamous NSCLC patients harboring activating EGFR mutations. Patients and Methods Patients received escalating quartet-agent doses every 3 weeks for 4 cycles...
November 4, 2017: Investigational New Drugs
https://www.readbyqxmd.com/read/29091995/safety-and-efficacy-of-alternating-treatment-with-ep2006-a-filgrastim-biosimilar-and-reference-filgrastim-a-phase-3-randomised-double-blind-clinical-study-in-the-prevention-of-severe-neutropenia-in-patients-with-breast-cancer-receiving-myelosuppressive-chemotherapy
#12
K Blackwell, P Gascon, A Krendyukov, S Gattu, Y Li, N Harbeck
Background: In 2015, the biosimilar filgrastim EP2006 became the first biosimilar approved by the US Food and Drug Administration (FDA) for commercial use in the United States, marketed as Zarxio®. This phase 3 randomised, double-blind registration study in patients with breast cancer receiving (neo)adjuvant myelosuppressive chemotherapy (TAC; docetaxel+doxorubicin+cyclophosphamide) compares reference filgrastim, Neupogen®, with two groups receiving alternating treatment with reference and biosimilar every other cycle...
October 28, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29090377/trastuzumab-in-combination-with-folfiri-in-patients-with-advanced-her2-positive-gastro-esophageal-adenocarcinoma-a-retrospective-multicenter-ageo-study
#13
Aziz Zaanan, Juliette Palle, Emilie Soularue, Florence Leroy, Samy Louafi, David Tougeron, Sylvain Manfredi, Pascal Artru, Astrid Pozet, Julien Taieb
BACKGROUND: Trastuzumab with fluoropyrimidine and cisplatin is the standard first-line treatment in patients with HER2-positive advanced gastro-esophageal adenocarcinoma. However, there are no safety and efficacy data of trastuzumab with FOLFIRI. OBJECTIVE: To evaluate safety and efficacy of FOLFIRI plus trastuzumab in patients with HER2-positive advanced gastro-esophageal adenocarcinoma. PATIENTS AND METHODS: This retrospective multicenter study included all consecutive patients with HER2-positive advanced gastro-esophageal adenocarcinoma treated with FOLFIRI plus trastuzumab between 2012 and 2015...
October 31, 2017: Targeted Oncology
https://www.readbyqxmd.com/read/29072402/outcomes-of-high-risk-patients-with-febrile-neutropenia-at-a-tertiary-care-center
#14
Asif Husain Osmani, Adnan Abdul Jabbar, Manesh Kumar Gangwani, Bilal Hassan
Fever during chemotherapy-induced neutropenia continues to be a major cause of morbidity and mortality in cancer patients. Mortality depends on the duration and degree of neutropenia, bacteremia, sepsis, performance status, comorbidities and other parameters. The highest mortality rates in cancer patients hospitalized with febrile neutropenia (FN) are observed in those with documented infection. The objectives of the study were to present available tools for risk assessment, to review pathogens causing infections in adult FN patients and to assess outcomes...
October 26, 2017: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/29072395/pegfilgrastim-versus-filgrastim-for-primary-prophylaxis-of-febrile-neutropenia-in-patients-with-non-hodgkin%C3%A2-s-lymphoma-a-cost-effectiveness-study
#15
Ramin Ravangard, Najme Bordbar, Khosro Keshavarz, Mehdi Dehghani
Aim: One method to deal with febrile neutropenia is the use of granulocyte colony stimulating factors (G-CSFs). Pegfilgrastim or Filgrastim injection can lead to a reduction in febrile neutropenia and severe neutropenia in patients receiving chemotherapy. This study aimed to compare the cost-effectiveness of using Pegfilgrastim, 3-day Filgrastim and 1-day Filgrastim medication strategies for the primary prophylaxis of febrile neutropenia in patients with relapsed non-Hodgkin’s lymphoma after salvage chemotherapy who referred to two referral centers affiliated to Iran, Shiraz University of Medical Sciences in 2014...
October 26, 2017: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/29071806/efficacy-and-safety-of-amrubicin-based-regimen-used-as-first-line-for-extensive-disease-small-cell-lung-cancer-a-meta-analysis-of-randomized-controlled-trials
#16
Chun-Quan Liu, Dan Tian, Ning Wang, Xian-Pu Meng, Jian-Dong Yang, Hua-Wei Li, Ning Zhao, Su Zhao, Fei Liao, Yong Cui
BACKGROUND: Currently, amrubicin is used as first-line in the treatment of patients with small-cell lung cancer (SCLC). However, the effect of amrubicin-based treatment in extensive-disease (ED) SCLC remains controversial. Thus, we conducted a meta-analysis of randomized controlled trials (RCTs) to assess the efficacy and safety of amrubicin-based regimen in the treatment of patients with ED-SCLC. METHODS: RCTs published in PubMed, Web of Science, Embase, and ClinicalTrials...
October 25, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29069279/phase-ii-study-of-nab-paclitaxel-in-refractory-small-bowel-adenocarcinoma-and-cpg-island-methylator-phenotype-cimp-high-colorectal-cancer
#17
M Overman, L Adam, K Raghav, J Wang, B Kee, D Fogelman, C Eng, E Vilar, R Shroff, A Dasari, R Wolff, J Morris, Enusha Karunasena, R Pisanic, N Azad, S Kopetz
Background: Hypermethylation of promoter CpG islands (CIMP) represents a unique pathway for the development of colorectal cancer (CRC), characterized by lack of chromosomal instability and a low rate of adenomatous polyposis coli (APC) mutations, which have both been correlated with taxane resistance. Similarly, small bowel adenocarcinoma (SBA), a rare tumor, also has a low rate of APC mutations. This phase II study evaluated taxane sensitivity in SBA and CIMP-high CRC. Patients and Methods: The primary objective was Response Evaluation Criteria in Solid Tumors version 1...
October 23, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29061534/granulocyte-colony-stimulating-factor-use-after-autologous-peripheral-blood-stem-cell-transplantation-comparison-of-two-practices
#18
Amrita D Singh, Sapna Parmar, Khilna Patel, Shreya Shah, Tsiporah Shore, Usama Gergis, Sebastian Mayer, Adrienne Phillips, Jing-Mei Hsu, Ruben Niesvizky, Tomer M Mark, Roger Pearse, Adriana Rossi, Koen van Besien
Administration of granulocyte colony-stimulating factor (G-CSF) after autologous peripheral blood stem cell transplantation (PBSCT) is generally recommended to reduce the duration of severe neutropenia; however, there is limited and conflicting data regarding the optimal timing of G-CSFs post-transplant. A retrospective study was performed at NewYork-Presbyterian/Weill Cornell Medical Center (NYP/WC) from November 5, 2013 to August 9, 2016 of adult inpatient autologous PBSCT patients who received G-CSF empirically starting on day +5 (early) versus day +12 only if absolute neutrophil count (ANC) was <0...
October 20, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29059026/impact-of-fluoroquinolone-prophylaxis-on-infectious-related-outcomes-after-hematopoietic-cell-transplantation
#19
Amber B Clemmons, Arpita S Gandhi, Benjamin Albrecht, Stephanie Jacobson, Jeremy Pantin
Background Patients immediately post-hematopoietic cell transplantation are at high risk for bacteremia. Judicious prophylactic antimicrobial utilization must balance anticipated benefits (reduction infections) versus risk (bacterial resistance, Clostridium difficile) . Objective To compare infectious outcomes (primary: incidence bacteremia; secondary: febrile neutropenia, C. difficile, susceptibility of bacteremia, time to discharge and 30-day mortality) between hematopoietic cell transplantation who received fluoroquinolone prophylaxis to those who did not...
January 1, 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29056470/phase-2-open-label-study-of-bortezomib-cladribine-and-rituximab-in-advanced-newly-diagnosed-and-relapsed-refractory-mantle-cell-and-indolent-lymphomas
#20
Soham D Puvvada, José Guillen-Rodriguez, Abhijeet Kumar, Lora Inclán, Kara Heard, Xavier I Rivera, Faiz Anwer, Jonathan H Schatz, Daruka Mahadevan, Daniel O Persky
BACKGROUND: Mantle-cell lymphoma (MCL) and indolent non-Hodgkin lymphoma (iNHL) are incurable heterogeneous diseases characterized by relapse. There is a need for newer treatments in MCL and iNHL, especially in the relapsed/refractory (R/R) setting. We therefore investigated the novel combination of bortezomib (Velcade), cladribine, and rituximab (VCR) in front-line and R/R settings in MCL and iNHL (NCT00980395). PATIENTS AND METHODS: Eligible patients included adults with biopsy-proven CD20-positive MCL and iNHL who met the criteria for treatment...
September 19, 2017: Clinical Lymphoma, Myeloma & Leukemia
keyword
keyword
79323
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"